Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa first-in-human CD30/CEA CAR-T for CEA-positive colorectal cancer with liver metastases
2026-526225-18-00Phase 2Authorised
- Sponsor
- Regensburg University Medical Center
- Start
- Jul 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD30/CEA CAR-T in colorectal adenocarcinoma, sponsored by Regensburg University Medical Center. Primary endpoints: Incidence and severity of adverse events and adverse events of special interest, Dose-limiting toxicities and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
CD30/CEA CAR-T
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2026-526225-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526225-18-00.